RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc.
Business Wire India RubrYc Therapeutics, Inc. (“RubrYc”) and iBio, Inc. (“iBio”, NYSEA: IBIO) announced today the closing of RubrYc’s Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed…